Shareholders approve merger of BioAlliance Pharma and Topotarget

Published: 1-Jul-2014
Finance Pharmaceutical

The combined business will be renamed Onxeo after completion of the transaction


BioAlliance Pharma, a French developer of drugs for orphan oncology diseases, is to merge with Denmark-based biopharmaceutical company Topotarget after receiving shareholder approval for the deal.

The combined business aims to become a leading orphan oncology company and will be renamed Onxeo after completion.

No financial details have been revealed.

The shareholders also approved the appointment of Orfacare Consulting, represented by Bo Jesper Hansen, and of Per Samuelsson, of Healthcap, as board members of Onxeo, effective as of the completion of the merger. As previously announced, Judith Greciet will be the CEO of Onxeo and Patrick Langlois the Chairman of the Board.

Completion is now subject to registration by the relevant French and Danish authorities, and should take place during July.

  • Companies:
  • BioAlliance Pharma
See more

You may also like

Research & Development

Merger of BioAlliance Pharma and Topotarget to create new company called Onxeo

Read more
Transaction is expected to be completed in July/August

Trending Articles

  1. Aurobindo Pharma signs $25m respiratory drug development and commercialisation deal with global pharma company The companies will co-develop and commercialise respiratory therapeutics, diversifying Aurobindo's current portfolio
  2. Merck's Welireg approved for cancers associated with von Hippel-Lindau disease in China The once-daily drug is the first HIF-2α to be approved in China, exhibiting a 49% objective response rate (ORR)
  3. Vetter strengthens senior management team for growth Three new managing directors to support global sustainable development
  4. Cleancube multi: Guardtech’s container facilities support NHS aseptic pharmacies Award-winning mobile cleanrooms offer fast, flexible solutions for facility upgrades
  5. Production of pharmaceutical compounds through microbial fermentation Most people’s experience of fermentation will be through its most famous and popular use – the brewing of beer

Upcoming event

CPhI Middle East

10–12 December 2024 | Conference | Riyadh, Saudi Arabia See all

You may also like

Research & Development

Merger of BioAlliance Pharma and Topotarget to create new company called Onxeo

Transaction is expected to be completed in July/August
Finance

BioAlliance Pharma to merge with Topotarget

The companies have a pipeline of orphan oncology drugs
Manufacturing

BioAlliance Pharma collaborates with Penn Pharma on development of Validive

BioAlliance Pharma entrusts the pharmaceutical development of Validive to Penn Pharma, including the production of phase III clinical batches and the commercial production
Research & Development

BioAlliance receives ANR funding

To develop new applications of its mucoadheasive Lauriad technology
Drug Delivery

Ondansetron RapidFilm gains European approval

Suitable for children and adults with swallowing difficulties
Packaging

How pharma packaging manufacturers role is evolving: the case of extractables testing

As the pharmaceutical industry continues to grow and evolve, extractables testing is a critical component of the pharmaceutical industry's efforts to prioritise quality and safety, ensuring one of the key functions pharma containers are designed for, says Anna Malori, Head of Product Management at Bormioli Pharma
Manufacturing

CDMO Adragos Pharma acquires aseptic fill-finish manufacturing expert, Baccinex

Baccinex has significant knowledge in sterile fill-finish processes for both lyophilised and liquid vials
Subscribe now